May 08, 2017 12:03 pm UTC| Business
SAN DIEGO and TORONTO, May 08, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG’806, a highly potent pan-FLT3/BTK inhibitor, exerts...
May 08, 2017 12:03 pm UTC| Business
SAN DIEGO and TORONTO, May 08, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating that CG’806, a highly potent pan-FLT3/BTK inhibitor, exerts...
May 08, 2017 12:03 pm UTC| Business
PORTLAND, Ore., SAN DIEGO, and TORONTO, May 08, 2017 -- Oregon Health Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) announced the presentation of preclinical data demonstrating that...
May 08, 2017 12:03 pm UTC| Business
PORTLAND, Ore., SAN DIEGO, and TORONTO, May 08, 2017 -- Oregon Health Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) announced the presentation of preclinical data demonstrating that...
May 08, 2017 12:03 pm UTC| Business
PORTLAND, Ore., SAN DIEGO, and TORONTO, May 08, 2017 -- Oregon Health Science University (OHSU) and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) announced the presentation of preclinical data demonstrating that...
Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update
May 08, 2017 12:03 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results...
Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update
May 08, 2017 12:03 pm UTC| Business
SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results...